Related Experiment Videos
Mouse neurotoxicity test for vaccinia-based smallpox vaccines
Zhongqi Li1, Steven A Rubin, Rolf E Taffs
1Laboratory of Pediatric and Respiratory Viral Diseases, OD/Center for Biologics Evaluation and Research, Food and Drug Administration, HFM-460, Bldg. 29B, Room 5NN22, 8800 Rockville Pike, Bethesda, MD 20892, USA.
Vaccine
|April 6, 2004
Summary
A new small animal assay was developed to evaluate neurotoxicity of vaccinia-based smallpox vaccines. This assay uses a licensed vaccine and a neurotoxic strain to predict potential adverse events.
Area of Science:
- Neuroscience
- Immunology
- Vaccinology
Background:
- The sole US FDA-licensed smallpox vaccine, Dryvax, had rare neurological adverse events.
- Mass smallpox vaccination in the US stopped in 1971 after eradication.
- New vaccinia-based vaccines are needed for biodefense but lack pre-clinical neurotoxicity assays.
Purpose of the Study:
- To develop and characterize a small animal neurotoxicity assay for vaccinia-based smallpox vaccines.
- To utilize Dryvax as a reference vaccine and Western Reserve (WR) strain as a positive control.
- To provide pre-clinical data for evaluating novel smallpox vaccine neurotoxicity.
Main Methods:
- Neonatal inoculation of mice with Dryvax and WR strains.
- Assessment of mortality, viral antigen expression in neural cells, and viral replication in the brain.
- Correlation of high-titer virus antibody with viral clearance from the brain.
Main Results:
- The WR strain caused significantly higher and faster mortality than Dryvax.
- Significant differences in viral antigen expression and brain replication were observed between strains.
- High-titer antibody presence correlated with reduced viral load in the brain.
Conclusions:
- The developed assay shows promise for assessing vaccinia-based smallpox vaccine neurotoxicity.
- Incorporating a licensed vaccine reference and positive control enhances assay validity.
- Further validation may establish this assay for crucial pre-clinical safety evaluations.